EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Tropomyosin receptor kinase B ( TrkB ) signalling: targeted therapy in neurogenic tumours

Yuehua Li, Chengjiang Wei, Wei Wang, Qingfeng Li, Zhi-Chao Wang iD

The Journal of Pathology: Clinical Research · 2023-03 · 9 (2) · 89-99

DOI: 10.1002/cjp2.307 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Pathology: Clinical Research, online erschienen am 19.12.2022. Verfasst von Yuehua Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR Ch…. Hauptthemen laut MEDLINE: Receptor, trkB, Neoplasms. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shanghai, Science and Technology Commission of Shanghai Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tropomyosin receptor kinase B (TrkB), a transmembrane receptor protein, has been found to play a pivotal role in neural development. This protein is encoded by the neurotrophic receptor tyrosine kinase 2 ( NTRK2 ) gene, and its abnormal activation caused by NTRK2 overexpression or fusion can contribute to tumour initiation, progression, and resistance to therapeutics in multiple types of neurogenic tumours. Targeted therapies for this mechanism have been designed and developed in preclinical and clinical studies, including selective TrkB inhibitors and pan‐TRK inhibitors. This review describes the gene structure, biological function, abnormal TrkB activation mechanism, and current‐related targeted therapies in neurogenic tumours.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, trkBNeoplasmsHumansReceptor, trkAReceptor, trkCTropomyosinMembrane GlycoproteinsMembrane Proteins

Stichwörter der Autor:innen

NTRKTrkBabnormal activationgene fusionneurogenic tumourstargeted therapytyrosine kinase

Substanzen

Receptor, trkBReceptor, trkAReceptor, trkCTropomyosinMembrane GlycoproteinsMembrane Proteins

Autor:innen und Institutionen

  • Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.

ORCID-Profile: Zhi-Chao Wang

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Shanghai
  • Science and Technology Commission of Shanghai Municipality

Zitieren

APA

Li, Y., Wei, C., Wang, W., Li, Q., & Wang, Z. C. (2023). Tropomyosin receptor kinase B ( TrkB ) signalling: targeted therapy in neurogenic tumours. The Journal of Pathology: Clinical Research, 9(2), 89-99. https://doi.org/10.1002/cjp2.307

Vancouver

Li Y, Wei C, Wang W, Li Q, Wang ZC. Tropomyosin receptor kinase B ( TrkB ) signalling: targeted therapy in neurogenic tumours. The Journal of Pathology: Clinical Research. 2023;9(2):89-99. doi:10.1002/cjp2.307

BibTeX
@article{Li2023,
  author = {Li, Yuehua and Wei, Chengjiang and Wang, Wei and Li, Qingfeng and Wang, Zhi-Chao},
  title = {Tropomyosin receptor kinase B ( TrkB ) signalling: targeted therapy in neurogenic tumours},
  journal = {The Journal of Pathology: Clinical Research},
  year = {2023},
  volume = {9},
  number = {2},
  pages = {89--99},
  doi = {10.1002/cjp2.307}
}
Kostenlos starten →